Open AccessAdjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
Author(s) -
Renata Rodrigues da Cunha Colombo Bonadio,
Rodrigo Barbosa de Azevedo,
Guilherme Harada,
Sirlene Maria da Costa,
Vanessa da Costa Miranda,
Daniel Salvatore de Freitas,
Elias Abdo Filho,
Patrícia Alves Ferreira,
Flavia Gabrielli,
Maria Del Pilar Estevez-Diz
Publication year - 2018
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.17.00146
Subject(s) - medicine , carboplatin , endometrial cancer , radiation therapy , oncology , chemotherapy , lymphadenectomy , carcinosarcoma , cancer , paclitaxel , carcinoma , cisplatin
The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial cancer treated with adjuvant chemotherapy followed by radiotherapy.